- Pressemitteilung BoxID 134523
Nutra Pharmaceutical's (OTCBB: NPHC) Distributor for Cobroxin, XenaCare Holdings, Announces National Sponsorship of the Arthritis Foundation
XenaCare Holdings has announced that it has become a national sponsor of the Arthritis Foundation, one of the largest nonprofit organizations dedicated to arthritis research and public health education
"As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis," explained Frank Rizzo, President of XenaCare Holdings. "We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts," he added.
With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website, Arthritis.org.
The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:
- Advocacy - Local, state and national efforts to advance vital legislation.
- Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
- Public health - Information and empowering programs and services.
- Community-based outreach - Network of 42 chapter offices
Additional National Proud Sponsors include Wyeth, Abbott, Nature Made® TripleFlex(TM) , Genentech, Bristol-Myers Squibb and Osteo Bi-Flex.
In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at Cobroxin.com.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States.
In 2009, the Company received the exclusive license to market and distribute Cobroxin within the United States. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) pain. The drug, which recently won the award for "Best New Product" at the Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida, is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.
Benefits to Cobroxin include:
- All Natural
- More Potent than Morphine
- Long Lasting
The Company's additional clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. The Company also offers formulations for the lifestyle performance market, which consists of sports line for athletes, including the SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays.
Diese Pressemitteilungen könnten Sie auch interessieren
Die Grippewelle hat Europa fest im Griff. In Frankreich starben innerhalb von 15 Tagen 13 Menschen. Auch in Deutschland gab es erste Todesopfer....
Welche Vor- und Nachteile verschiedene Behandlungen bei entzündlichen Erkrankungen des Zahnhalteapparates (Parodontopathien) bieten, ist Gegenstand...
Kunden des Deutschen Medizinrechenzentrum (DMRZ.de) werden noch digitaler. Mit dem Dokumenten-Management (DMS) von DMRZ.de ist es ab sofort möglich,...